stem cells are set to take root in the Indian drug market. They will be launched as a constituent of umbilical cord blood (ucb) to help treat fatal diseases such as thalassemia, anaemia and leukaemia. Reliance Life Sciences (rls), a subsidiary of the Reliance group of Industries, has become the first Indian company to be given permission to market the ucb.

To be called